Adjuvant RT may improve post-prostatectomy outcomes vs early salvage RT in men with adverse pathology

Adjuvant radiotherapy (RT) after radical prostatectomy was associated with a reduced risk of all-cause mortality compared with early salvage RT.

Dr. Powles on pivotal enfortumab vedotin data in bladder cancer

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses findings from the pivotal EV-301 trial of enfortumab vedotin.

Nomograms predictive of outcomes with novel PSMA-targeted agent in mCRPC

A recent analysis suggested that nomograms could predict outcomes with the PSMA-targeted agent Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.